[1] CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.

[2] In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR market where it raised 5.2 billion yuan (US$750 million).

Since late 2020, it has been in Phase III trials in Chile,[9] Mexico,[10] Pakistan,[11] Russia,[12] and Saudi Arabia[11] with 40,000 participants.

[14][8] Its single-dose regimen and normal refrigerator storage requirement make it a favorable vaccine option for many countries.

[15] In April 2021, CanSino Biologics began clinical trials for a version of its Covid-19 vaccine administered by inhalation rather than injection.